Arbutus Biopharma (ABUS) News Today → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ABUS Stock Alerts $2.98 +0.09 (+3.11%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 8:31 PM | morningstar.comArbutus Biopharma Corp ABUSMay 17 at 3:30 PM | bizjournals.comMike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus BiopharmaMay 17 at 3:30 PM | finance.yahoo.comArbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17 at 3:30 PM | finance.yahoo.comUpdate: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17 at 9:00 AM | businesswire.comWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueMay 15, 2024 | americanbankingnews.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 12.4% in AprilMay 11, 2024 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving Average of $2.44May 10, 2024 | msn.comArbutus Biopharma to Engage Investors at Upcoming New York ConferencesMay 7, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesMay 3, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)May 3, 2024 | finance.yahoo.comArbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 3, 2024 | finance.yahoo.comArbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Friday.May 3, 2024 | msn.comArbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial ReleaseMay 2, 2024 | finance.yahoo.comArbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial ReviewMay 2, 2024 | investorplace.comABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | washingtonpost.comArbutus: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comArbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 2, 2024 | globenewswire.comArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024May 1, 2024 | markets.businessinsider.comArbutus Biopharma earnings: here's what to expectMay 1, 2024 | msn.comArbutus Biopharma Q1 2024 Earnings PreviewApril 30, 2024 | money.usnews.comArbutus Biopharma CorpApril 21, 2024 | msn.comArbutus Biopharma Sets Date for Q1 2024 Financial ResultsApril 18, 2024 | globenewswire.comArbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateApril 10, 2024 | seekingalpha.comArbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty RemainsApril 4, 2024 | msn.comArbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From JudgeApril 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeArbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseApril 4, 2024 | markets.businessinsider.comArbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against ModernaApril 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Earns "Market Outperform" Rating from JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.April 4, 2024 | globenewswire.comArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaApril 3, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $3.25Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.25April 3, 2024 | seekingalpha.comArbutus Biopharma jumps after claim construction order in patent fight with ModernaApril 3, 2024 | marketbeat.comTrading was temporarily halted for "ABUS" at 12:04 PM with a stated reason of "LULD pause." Trading set to resume at 12:04 PM. April 1, 2024 | finance.yahoo.comIs Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?March 19, 2024 | finance.yahoo.comABUS Jan 2025 7.000 callMarch 14, 2024 | marketbeat.comHudson Bay Capital Management LP Purchases 1,302,978 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)Hudson Bay Capital Management LP lifted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 45.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,149,904 shares of the biophMarch 12, 2024 | msn.comArbutus Biopharma to Participate in Prominent Investor ConferencesMarch 8, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesMarch 6, 2024 | marketbeat.comArbutus Biopharma Target of Unusually Large Options Trading (NASDAQ:ABUS)Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 31,568 call options on the stock. This represents an increase of 2,744% compared to the typical daily volume of 1,110 call options.March 6, 2024 | marketbeat.comFY2024 EPS Estimates for Arbutus Biopharma Co. Raised by Chardan Capital (NASDAQ:ABUS)Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Equities research analysts at Chardan Capital upped their FY2024 EPS estimates for Arbutus Biopharma in a research note issued on Sunday, March 3rd. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($March 3, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMarch 2, 2024 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue ForecastsMarch 1, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Meets EstimatesArbutus Biopharma (NASDAQ:ABUS - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $4.74 million. Arbutus Biopharma had a negative net margin of 339.32% and a negative return on equity of 56.45%. During the same period last year, the firm earned ($0.14) earnings per share.March 1, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Given New $5.00 Price Target at HC WainwrightHC Wainwright reduced their price objective on Arbutus Biopharma from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday.March 1, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a report on Friday.March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation ProspectsMarch 1, 2024 | finance.yahoo.comQ4 2023 Arbutus Biopharma Corp Earnings CallFebruary 29, 2024 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs ABUS Media Mentions By Week ABUS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼0.320.42▲Average Medical News Sentiment ABUS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼62▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CMPS News ATXS News APLT News LRMR News VERV News CDMO News ALT News KALV News TVTX News OCS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.